JP2020516289A5 - - Google Patents

Download PDF

Info

Publication number
JP2020516289A5
JP2020516289A5 JP2019555834A JP2019555834A JP2020516289A5 JP 2020516289 A5 JP2020516289 A5 JP 2020516289A5 JP 2019555834 A JP2019555834 A JP 2019555834A JP 2019555834 A JP2019555834 A JP 2019555834A JP 2020516289 A5 JP2020516289 A5 JP 2020516289A5
Authority
JP
Japan
Prior art keywords
variant
risk allele
linkage disequilibrium
subject
risk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019555834A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020516289A (ja
JP7321939B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/023266 external-priority patent/WO2018190990A1/en
Publication of JP2020516289A publication Critical patent/JP2020516289A/ja
Publication of JP2020516289A5 publication Critical patent/JP2020516289A5/ja
Priority to JP2023121229A priority Critical patent/JP7557581B2/ja
Application granted granted Critical
Publication of JP7321939B2 publication Critical patent/JP7321939B2/ja
Priority to JP2024158740A priority patent/JP2024163308A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019555834A 2017-04-13 2018-03-20 Il33及びil1rl1をコードする遺伝子にリスクアレルを有する患者の炎症性肺疾患の処置及び阻害 Active JP7321939B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023121229A JP7557581B2 (ja) 2017-04-13 2023-07-26 Il33及びil1rl1をコードする遺伝子にリスクアレルを有する患者の炎症性肺疾患の処置及び阻害
JP2024158740A JP2024163308A (ja) 2017-04-13 2024-09-13 Il33及びil1rl1をコードする遺伝子にリスクアレルを有する患者の炎症性肺疾患の処置及び阻害

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762485077P 2017-04-13 2017-04-13
US62/485,077 2017-04-13
PCT/US2018/023266 WO2018190990A1 (en) 2017-04-13 2018-03-20 Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding il33 and il1rl1

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023121229A Division JP7557581B2 (ja) 2017-04-13 2023-07-26 Il33及びil1rl1をコードする遺伝子にリスクアレルを有する患者の炎症性肺疾患の処置及び阻害

Publications (3)

Publication Number Publication Date
JP2020516289A JP2020516289A (ja) 2020-06-11
JP2020516289A5 true JP2020516289A5 (cg-RX-API-DMAC7.html) 2021-04-22
JP7321939B2 JP7321939B2 (ja) 2023-08-07

Family

ID=61911717

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019555834A Active JP7321939B2 (ja) 2017-04-13 2018-03-20 Il33及びil1rl1をコードする遺伝子にリスクアレルを有する患者の炎症性肺疾患の処置及び阻害
JP2023121229A Active JP7557581B2 (ja) 2017-04-13 2023-07-26 Il33及びil1rl1をコードする遺伝子にリスクアレルを有する患者の炎症性肺疾患の処置及び阻害
JP2024158740A Pending JP2024163308A (ja) 2017-04-13 2024-09-13 Il33及びil1rl1をコードする遺伝子にリスクアレルを有する患者の炎症性肺疾患の処置及び阻害

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023121229A Active JP7557581B2 (ja) 2017-04-13 2023-07-26 Il33及びil1rl1をコードする遺伝子にリスクアレルを有する患者の炎症性肺疾患の処置及び阻害
JP2024158740A Pending JP2024163308A (ja) 2017-04-13 2024-09-13 Il33及びil1rl1をコードする遺伝子にリスクアレルを有する患者の炎症性肺疾患の処置及び阻害

Country Status (12)

Country Link
US (2) US11708415B2 (cg-RX-API-DMAC7.html)
EP (3) EP3957752B1 (cg-RX-API-DMAC7.html)
JP (3) JP7321939B2 (cg-RX-API-DMAC7.html)
KR (2) KR102751957B1 (cg-RX-API-DMAC7.html)
CN (2) CN110431240B (cg-RX-API-DMAC7.html)
AU (3) AU2018252974B2 (cg-RX-API-DMAC7.html)
CA (1) CA3059350A1 (cg-RX-API-DMAC7.html)
ES (1) ES3052989T3 (cg-RX-API-DMAC7.html)
IL (3) IL314591B1 (cg-RX-API-DMAC7.html)
MX (2) MX2019012171A (cg-RX-API-DMAC7.html)
SG (1) SG11201909457XA (cg-RX-API-DMAC7.html)
WO (1) WO2018190990A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
CA3246946A1 (en) 2014-11-14 2025-11-29 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
MX2019012171A (es) * 2017-04-13 2019-11-25 Regeneron Pharma Tratamiento e inhibicion de enfermedades pulmonares inflamatorias en pacientes que tienen alelos de riesgo en los genes que codifican la il33 e il1rl1.
WO2018231827A1 (en) 2017-06-12 2018-12-20 Bluefin Biomedicine, Inc. Anti-il1rap antibodies and antibody drug conjugates
JP7165618B2 (ja) * 2019-04-23 2022-11-04 ジェネシスヘルスケア株式会社 アレルギー性鼻炎のリスクを判定する方法
MX2021013427A (es) * 2019-05-01 2022-01-31 Sanofi Biotechnology Metodos para tratar o prevenir el asma mediante la administracion un antagonista de il-33.
KR20220034878A (ko) 2019-07-16 2022-03-18 사노피 바이오테크놀로지 Il-4r 길항제를 투여하여 천식을 치료 또는 예방하는 방법
EP4430211A1 (en) * 2021-11-11 2024-09-18 Regeneron Pharmaceuticals, Inc. Treatment of lung disease based upon stratification of polygenic risk score for interleukin 33 (il-33)

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323334B1 (en) 1999-09-24 2001-11-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules encoding a 103 gene product and uses therefor
PT2990420T (pt) 2000-05-26 2017-03-16 Immunex Corp Uso de anticorpos de recetor de interleucina-4 e composições dos mesmos
UA93653C2 (ru) 2003-11-07 2011-03-10 Иммунекс Корпорейшн Выделенное антитело, kotopoe специфически связывается c человеческим рецептором il-4 (il-4r)
NZ549040A (en) 2004-02-17 2009-07-31 Schering Corp Use for interleukin-33 (IL33) and the IL-33 receptor complex
CN101426518A (zh) * 2006-01-11 2009-05-06 艾罗文斯公司 用于治疗人类和非-人类灵长类中哮喘的方法和组合物
FR2900817B1 (fr) * 2006-05-12 2008-12-19 Gambro Lundia Ab Bandage a usage medical pour un tube implante dans un patient, ainsi que le procede d'application de ce bandage sur la peau d'un patient
CN1896275B (zh) * 2006-06-29 2010-04-07 四川大学华西医院 一种检测与慢性阻塞性肺部疾病相关的snp的pcr试剂盒
US7560530B1 (en) 2006-07-20 2009-07-14 Schering Corporation IL-33 receptor
CA2664343C (en) 2006-10-02 2016-04-26 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human il-4 receptor
US7608693B2 (en) 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
CN101600456A (zh) * 2006-12-11 2009-12-09 惠氏公司 治疗il-13相关疾病和监测il-13相关疾病治疗的方法和组合物
EP2050764A1 (en) * 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
WO2010067381A1 (en) * 2008-12-12 2010-06-17 Decode Genetics Ehf Genetic variants as markers for use in diagnosis, prognosis and treatment of eosinophilia, asthma, and myocardial infarction
EP2475388B1 (en) 2009-09-10 2017-11-08 Merck Sharp & Dohme Corp. Use of il-33 antagonists to treat fibrotic disease
ES2549637T3 (es) 2011-02-23 2015-10-30 F. Hoffmann-La Roche Ag Anticuerpos contra IL33R humano y la utilización de los mismos
US9212227B2 (en) 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
KR102502640B1 (ko) * 2012-08-21 2023-02-23 사노피 바이오테크놀로지 Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
US10703799B2 (en) * 2012-12-10 2020-07-07 Vib Vzw IL-33R and IL-1RAcP fusion proteins
JO3532B1 (ar) 2013-03-13 2020-07-05 Regeneron Pharma الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
JP6404314B2 (ja) 2013-03-15 2018-10-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. Il−33拮抗薬とその使用法
TWI634900B (zh) 2013-07-11 2018-09-11 再生元醫藥公司 藉由投與il-4r抑制劑治療嗜酸性食道炎的方法
HUE064292T2 (hu) 2013-12-26 2024-03-28 Mitsubishi Tanabe Pharma Corp Humán anti-IL-33 semlegesítõ monoklonális antitest
SG11201605580RA (en) 2014-01-10 2016-10-28 Anaptysbio Inc Antibodies directed against interleukin-33 (il-33)
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
EP3129497B1 (en) * 2014-04-11 2021-09-08 Novartis AG Methods of selectively treating asthma using il-13 antagonists
NO2785538T3 (cg-RX-API-DMAC7.html) 2014-05-07 2018-08-04
JP6929771B2 (ja) 2014-11-10 2021-09-01 ジェネンテック, インコーポレイテッド 抗インターロイキン−33抗体及びその使用
US11708608B2 (en) 2014-11-10 2023-07-25 Genentech, Inc. Therapeutic and diagnostic methods for IL-33-mediated disorders
CA3246946A1 (en) 2014-11-14 2025-11-29 Sanofi Biotechnology Methods for treating chronic sinusitis with nasal polyps by administering an il-4r antagonist
CN104531689A (zh) * 2014-12-12 2015-04-22 上海交通大学医学院附属新华医院 与哮喘相关的基因单核苷酸多态性位点、预测哮喘的试剂盒及其应用
MX387295B (es) 2015-03-31 2025-03-18 Medimmune Ltd Nueva forma de interleucina-33 (il33), formas mutadas de interleucina-33 (il33), anticuerpos, ensayos y métodos para usar los mismos.
JP6858182B2 (ja) * 2015-10-06 2021-04-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. インターロイキン33(il−33)媒介疾患に関するバイオマーカーおよびその使用
TWI784988B (zh) 2016-12-01 2022-12-01 美商再生元醫藥公司 治療發炎症狀的方法
MX2019012171A (es) * 2017-04-13 2019-11-25 Regeneron Pharma Tratamiento e inhibicion de enfermedades pulmonares inflamatorias en pacientes que tienen alelos de riesgo en los genes que codifican la il33 e il1rl1.

Similar Documents

Publication Publication Date Title
Rutgeerts et al. A randomised phase I study of etrolizumab (rhuMAb β7) in moderate to severe ulcerative colitis
US11016099B2 (en) Prediction of clinical response to IL23-antagonists using IL23 pathway biomarkers
Peyrin-Biroulet et al. Early Crohn disease: a proposed definition for use in disease-modification trials
JP6563976B2 (ja) 可溶性ヒトst−2抗体およびアッセイ法
JP6755240B2 (ja) 新規分子バイオマーカーを使用して慢性閉塞性肺疾患(copd)を診断する方法
JP2013500941A5 (cg-RX-API-DMAC7.html)
JP2016511823A5 (cg-RX-API-DMAC7.html)
US11124835B2 (en) Methods of diagnosing chronic obstructive pulmonary disease (COPD) using novel molecular biomarkers
FI3774897T3 (fi) Menetelmiä ja järjestelmiä tulehdustautisten potilaiden valintaan ja hoitoon
JP2018535394A5 (cg-RX-API-DMAC7.html)
Gaber et al. Clinical significance of serum interleukin-6 and− 174 G/C promoter polymorphism in Rheumatoid arthritis patients
JP2011184466A5 (cg-RX-API-DMAC7.html)
Lucendo Pharmacological treatments for eosinophilic esophagitis: current options and emerging therapies
JP2015501297A5 (ja) 医薬組成物、方法、診断キット
US10604806B2 (en) Methods of diagnosing chronic obstructive pulmonary disease (COPD) using novel molecular biomarkers
JP7321939B2 (ja) Il33及びil1rl1をコードする遺伝子にリスクアレルを有する患者の炎症性肺疾患の処置及び阻害
Farrokhi et al. Mannose-binding lectin mediated complement pathway in autoimmune neurological disorders
Pandit et al. Multisystem inflammatory syndrome in children during the COVID-19 pandemic: A review of clinical manifestations, Cardiac Complications and Medical Management
Sowho et al. Association of sleep apnoea risk and aortic enlargement in Marfan syndrome
Sahoo et al. Paradigm of immune dysregulation in coronavirus disease-2019 infection
Cabral-Marques et al. The relationship between autoantibodies targeting GPCRs and the renin-angiotensin system associates with COVID-19 severity
Carlstrom et al. Severe asthma: what makes it so hard to manage?
Sarkar et al. The Role of Anti-inflammatory Agents in the Management of COVID-19
DINACHE et al. Rheumatoid Arthritis-Associated Interstitial Lung Disease
JP2016520563A5 (cg-RX-API-DMAC7.html)